Egetis Therapeutics AB (publ) (STO:EGTX)
Sweden · Delayed Price · Currency is SEK 5.37
-0.14 (-2.54%)
Aug 1, 2025, 5:29 PM CET
Egetis Therapeutics AB Revenue
Egetis Therapeutics AB had revenue of 12.70M SEK in the quarter ending March 31, 2025, with 4.96% growth. This brings the company's revenue in the last twelve months to 46.70M, down -25.76% year-over-year. In the year 2024, Egetis Therapeutics AB had annual revenue of 46.10M, down -19.97%.
Revenue (ttm)
46.70M
Revenue Growth
-25.76%
P/S Ratio
41.31
Revenue / Employee
1.23M
Employees
40
Market Cap
1.93B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 46.10M | -11.50M | -19.97% |
| Dec 31, 2023 | 57.60M | 35.00M | 154.87% |
| Dec 31, 2022 | 22.60M | -15.60M | -40.84% |
| Dec 31, 2021 | 38.20M | -2.46M | -6.05% |
| Dec 31, 2020 | 40.66M | -41.90M | -50.75% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Swedish Orphan Biovitrum AB | 26.97B |
| Sectra AB | 3.31B |
| Getinge AB | 35.50B |
| Camurus AB | 2.27B |
| Medicover AB | 25.22B |
| Asker Healthcare Group AB | 15.88B |
| Bonesupport Holding AB | 1.06B |
| AddLife AB | 10.44B |